筋萎縮性側索硬化症(ALS)治療薬のパイプライン分析

【英語タイトル】Amyotrophic Lateral Sclerosis (ALS) Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

P&S Market Researchが出版した調査資料(PSM802009)・商品コード:PSM802009
・発行会社(調査会社):P&S Market Research
・発行日:2017年5月1日
・ページ数:116
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥277,500見積依頼/購入/質問フォーム
Group License(5名様閲覧用)USD3,250 ⇒換算¥360,750見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,000 ⇒換算¥777,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

The study analysed that the Amyotrophic lateral sclerosis pipeline comprises of 72 drug candidates in different stages of development.
Amyotrophic lateral sclerosis is a disease that causes progression in neurodegeneration in brain and spinal cord. In Amyotrophic lateral sclerosis, the muscle does not get adequate nourishment due to which it becomes atrophic. The disease occurs in the lateral region, an area in which spinal cord reflexes are found majorly. Therefore, the degeneration leads to hardening and scarring of muscles in that region. The progressive degeneration of neurons from brain to the spinal cord and spinal cord to the whole body can ultimately lead to their death. Amyotrophic lateral sclerosis is classified into two types, namely, sporadic and familial. Approximately 90% to 95% of the patients suffering from the disease in the U.S. are experience the sporadic.

Insights on pipeline segments

According to the route of administration analysis, most of the drug candidates are being developed to be administered by oral route.

NurOwn technology platform for Amyotrophic Lateral Sclerosis drug development

NurOwn is a cell therapy platform that builds on the enormous research effort that has gone into developing mesenchymal stem cells (MSCs) as a treatment for human diseases.

Major companies collaborate for the development of Amyotrophic Lateral Sclerosis Pipeline

The research also found that various companies have collaborated for the development of amyotrophic lateral sclerosis pipeline. In March 2013, Dainippon Sumitomo Pharma Co., Ltd. signed a research, development and commercial licensing agreement with Edison Pharmaceuticals, Inc. for EPI-743 and EPI-589 in Japan.

Some of the key players developing drugs for Amyotrophic lateral sclerosis include FlexPharma, Inc., Orion Corporation, Genervon Biopharmaceuticals, LLC, and others.

【レポートの目次】

Chapter 1. Research Background

1.1. Research Objectives

1.2. Definition

1.3. Research Scope

1.3.1. Pipeline Analysis by Phase

1.3.2. Pipeline Analysis by Route of Administration

1.3.3. Pipeline Analysis by Molecule Type

1.4. Key Stakeholders

Chapter 2. Research Methodology

2.1. Secondary Research

2.2. Primary Research

2.2.1. Breakdown of Primary Research Respondents

2.2.1.1. By industry participants

2.2.1.2. By company type

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

4.1. Amyotrophic Lateral Sclerosis Overview

4.1.1. Signs and Symptoms

4.1.2. Pathophysiology

4.1.3. Diagnosis

4.1.4. Treatment

4.1.5. Epidemiology

4.2. Key Drivers

4.3. Key Barriers

4.4. Amyotrophic Lateral Sclerosis Pipeline Analysis

4.4.1. Pipeline Analysis by Phase

4.4.2. Pipeline Analysis by Molecule Type

4.4.3. Pipeline Analysis by Route of Administration

4.4.4. Pipeline Analysis by Company

Chapter 5. Amyotrophic Lateral Sclerosis Pipeline Analysis by Phase (2017)

5.1. Pre-registration/Registration: Drug Profiles

5.1.1. Pre-Clinical Studies

5.1.2. Clinical Trials

5.1.3. Clinical Results

5.1.4. Strategic Developments

5.1.5. Designations

5.1.6. Grants

5.1.7. Patents

5.1.8. Technology

5.2. Phase III: Drug Profiles

5.2.1. Pre-Clinical Studies

5.2.2. Clinical Trials

5.2.3. Clinical Results

5.2.4. Strategic Developments

5.2.5. Designations

5.2.6. Grants

5.2.7. Patents

5.2.8. Technology

5.3. Phase II: Drug Profiles

5.3.1. Pre-Clinical Studies

5.3.2. Clinical Trials

5.3.3. Clinical Results

5.3.4. Strategic Developments

5.3.5. Designations

5.3.6. Grants

5.3.7. Patents

5.3.8. Technology

5.4. Phase I: Drug Profiles

5.4.1. Pre-Clinical Studies

5.4.2. Clinical Trials

5.4.3. Clinical Results

5.4.4. Strategic Developments

5.4.5. Designations

5.4.6. Grants

5.4.7. Patents

5.4.8. Technology

5.5. Pre-Clinical: Drug Profiles

5.5.1. Pre-Clinical Studies

5.5.2. Strategic Developments

5.5.3. Designations

5.5.4. Grants

5.5.5. Patents

5.5.6. Technology

5.6. Discovery: Drug Profiles

5.6.1. Strategic Developments

5.6.2. Designations

5.6.3. Grants

5.6.4. Patents

5.6.5. Technology

5.7. Inactive: Drug Profiles

5.7.1. Pre-Clinical Studies

5.7.2. Clinical Trials

5.7.3. Clinical Results

5.7.4. Strategic Developments

5.7.5. Designations

5.7.6. Grants

5.7.7. Patents

5.7.8. Technology

5.8. Discontinued: Drug Profiles

5.8.1. Pre-Clinical Studies

5.8.2. Clinical Trials

5.8.3. Clinical Results

5.8.4. Strategic Developments

5.8.5. Designations

5.8.6. Grants

5.8.7. Patents

5.8.8. Technology

Chapter 6. Clinical Trials Analysis

6.1. Clinical Trials by Region

6.2. Clinical Trials by Trial Status

Chapter 7. Competitive Landscape Analysis

7.1. Key Players Benchmarking

7.2. SWOT Analysis

Chapter 8. Company Profiles

8.1 Business Overview

8.2 Product and Service Offerings

Chapter 9. Appendix

9.1 Abbreviations

Note: Certain sections of the above table of contents would vary according to the availability of information.



【レポートのキーワード】

筋萎縮性側索硬化症(ALS)

★調査レポート[筋萎縮性側索硬化症(ALS)治療薬のパイプライン分析] (コード:PSM802009)販売に関する免責事項を必ずご確認ください。
★調査レポート[筋萎縮性側索硬化症(ALS)治療薬のパイプライン分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆